Everything below concerns MOD GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The medication has largely been replaced by newer and improved NSAAs, namely bicalutamide and enzalutamide, due to their better efficacy, tolerability, safety, and dosing frequency (once per day), and is now relatively little-used. Flutamide is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
In July 2020, his series Die Hart premiered on Quibi on July 20 and had a strong first weekend. In March 2023, Roku and Hart's multi-platform comedy brand Laugh Out Loud debuted the series' second season on The Roku Channel. In addition to returning to his starring role, Hart executive produced the second season; Laugh Out Loud CEO and Hart's longtime business partner, Jeff Clanagan, served as a producer on the project. Hart signed a first look deal with Netflix in January 2021. He later played Arnold Drummond in the Diff'rent Strokes portion of the third edition of Live in Front of a Studio Audience. In 2022, Hart starred alongside Mark Wahlberg in the comedy film, Me Time. The film shows how Sonny (Hart) experiences a wild journey with his friend after finding a much-longed-for free weekend. In January 2024, Hart starred (alongside Úrsula Corberó from Money Heist and Vincent D'Onofrio) as a master thief in the Netflix comedy heist film Lift, directed by F. Gary Gray. A month later, he competed in season eleven of The Masked Singer as "Book". He purposely unmasked himself in the season eleven premiere as part of a prank on host Nick Cannon.
This was confirmed to be as effective as the antibiotic vancomycin at inhibiting Clostridioides difficile infection without having a significant effect on the overall microbial composition of the gut. Glycerol solutions have been used for the preservation and storage of tissue grafts at ambient conditions as an alternative to frozen storage. Glycerol has also been incorporated as a component of bio-ink formulations in the field of bioprinting. The glycerol content acts to add viscosity to the bio-ink without adding large protein, saccharide, or glycoprotein molecules. It is on the World Health Organization's List of Essential Medicines for its use in treating atopic eczema.
Sources: en.wikipedia.org
== See also == Able Archer 83 – NATO military exercise that happened over a month after the Petrov incident Dead Hand – Soviet nuclear weapons-control system List of nuclear close calls Norwegian rocket incident – a rocket carrying scientific equipment to study the aurora borealis that resembled a submarine-launched Trident missile Vasily Arkhipov – the subject of another nuclear war-averting incident during the Cuban Missile Crisis World War III – situations resulting in close encounters of a third world war
=== Central nervous system === In general, adenosine has an inhibitory effect in the central nervous system (CNS). Caffeine's stimulatory effects are credited primarily (although not entirely) to its capacity to block adenosine receptors, thereby reducing the inhibitory tonus of adenosine in the CNS. This reduction in adenosine activity leads to increased activity of the neurotransmitters dopamine and glutamate. Experimental evidence suggests that adenosine and adenosine agonists can activate Trk receptor phosphorylation through a mechanism that requires the adenosine A2A receptor. Adenosine in the brain acts through three major receptor subtypes—A1, A2A, and A3—distributed across various neuronal and glial populations. Activation of neuronal A1 receptors generally exerts inhibitory effects, contributing to synaptic regulation. In a preclinical knock-in model of Alzheimer's disease, neuronal hyperexcitability during the asymptomatic stage has been shown to originate at the synaptic compartment and is associated with a deficient adenosinergic tone, suggesting that impaired adenosine signaling may contribute to early synaptic dysfunction.
In 2000, the company introduced a line of fair trade products. Of the approximately 300 million pounds (136 million kilograms) of coffee Starbucks purchased in 2006, about 18 million pounds (8.2 million kilograms) or 6% was certified as fair trade. Groups such as Global Exchange called for Starbucks to further increase its sales of fair trade coffees. After a long-running dispute between Starbucks and Ethiopia, Starbucks agreed to support and promote Ethiopian coffees. An article in BBC News, states that Ethiopian ownership of popular coffee designations such as Harrar and Sidamo is acknowledged, even if they are not registered. Ethiopia fought hard for this acknowledgement mainly to help give its poverty-stricken farmers a chance to make more money. In 2006, Starbucks said it paid $1.42 per pound ($3.1/kg) for its coffee, more than 33% higher than the commodity price at the time. However, the coffee Starbucks bought for $1.42 per pound ($3.1/kg), had a selling price—after transportation, processing, marketing, store rentals, taxes, and staff salary and benefits—of $10.99 per pound ($24.2/kg). As of 2013, the Starbucks website sells only one Ethiopian coffee. In addition, Starbucks is an active member of the World Cocoa Foundation, although targets set in 2005, 2008 and 2010 to reduce child labor that the Foundation has backed have consistently not been met.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.